MX2020013100A - Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. - Google Patents

Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.

Info

Publication number
MX2020013100A
MX2020013100A MX2020013100A MX2020013100A MX2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A MX 2020013100 A MX2020013100 A MX 2020013100A
Authority
MX
Mexico
Prior art keywords
mucositis
host disease
prevention
treatment
versus host
Prior art date
Application number
MX2020013100A
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of MX2020013100A publication Critical patent/MX2020013100A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere al uso de una proteína CD24 para prevenir o tratar enfermedad de injerto contra hospedero y mucositis.
MX2020013100A 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. MX2020013100A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862680218P 2018-06-04 2018-06-04
US201862739742P 2018-10-01 2018-10-01
US201862739719P 2018-10-01 2018-10-01
PCT/US2019/035200 WO2019236472A1 (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis

Publications (1)

Publication Number Publication Date
MX2020013100A true MX2020013100A (es) 2021-02-17

Family

ID=68770596

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013100A MX2020013100A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
MX2020013103A MX2020013103A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013103A MX2020013103A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.

Country Status (15)

Country Link
US (2) US11911441B2 (es)
EP (2) EP3801773A4 (es)
JP (2) JP2021527066A (es)
KR (2) KR20210021317A (es)
CN (2) CN112752766A (es)
AU (2) AU2019282530A1 (es)
BR (2) BR112020024683A2 (es)
CA (2) CA3102372A1 (es)
CL (2) CL2020003168A1 (es)
IL (2) IL279205A (es)
MA (2) MA52810A (es)
MX (2) MX2020013100A (es)
SG (2) SG11202011964SA (es)
TW (2) TW202012015A (es)
WO (2) WO2019236472A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019282530A1 (en) * 2018-06-04 2021-01-07 Oncoimmune, Inc. Methods of use of CD24 for the prevention and treatment of leukemia relapse
TW202143996A (zh) * 2020-02-10 2021-12-01 美商昂科免疫公司 使用可溶性ｃｄ２４治療病毒性肺炎之方法
WO2023205742A1 (en) * 2022-04-20 2023-10-26 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US8614301B2 (en) * 2007-11-14 2013-12-24 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of treating cancer using anti CD24 antibodies
AU2011248540B2 (en) * 2010-04-28 2014-11-20 Oncolmmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN102250828B (zh) * 2010-11-10 2014-11-05 北京大学 Cd24及cd24抗体的新用途
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
EP3215539A4 (en) * 2014-11-06 2018-05-23 Children's Research Institute, Children's National Immunotherapeutics for cancer and autoimmune diseases
BR112017022394A2 (pt) * 2015-05-07 2018-07-17 Oncoimmune Inc uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade
WO2017136492A1 (en) * 2016-02-02 2017-08-10 Oncoimmune, Inc. Use of cd24 proteins for treating leptin-deficient conditions
AU2019282530A1 (en) * 2018-06-04 2021-01-07 Oncoimmune, Inc. Methods of use of CD24 for the prevention and treatment of leukemia relapse
EP4087406A4 (en) * 2020-01-08 2024-01-10 PureTech LYT, Inc. VESICLE COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
JP2021527056A (ja) 2021-10-11
MA52810A (fr) 2021-04-14
CA3102374A1 (en) 2019-12-12
EP3802583A1 (en) 2021-04-14
IL279204A (en) 2021-01-31
MX2020013103A (es) 2021-05-12
CL2020003169A1 (es) 2021-06-11
TW202015753A (zh) 2020-05-01
US11911441B2 (en) 2024-02-27
BR112020024683A2 (pt) 2021-03-09
WO2019236474A1 (en) 2019-12-12
AU2019282044A1 (en) 2021-01-07
EP3801773A1 (en) 2021-04-14
US20210228680A1 (en) 2021-07-29
SG11202011963UA (en) 2020-12-30
EP3801773A4 (en) 2022-03-16
AU2019282530A1 (en) 2021-01-07
TW202012015A (zh) 2020-04-01
WO2019236472A1 (en) 2019-12-12
KR20210021317A (ko) 2021-02-25
US20210268061A1 (en) 2021-09-02
CN112752766A (zh) 2021-05-04
EP3802583A4 (en) 2022-03-16
MA52811A (fr) 2022-03-16
CN112512640A (zh) 2021-03-16
CL2020003168A1 (es) 2021-06-11
KR20210018294A (ko) 2021-02-17
JP2021527066A (ja) 2021-10-11
BR112020024659A2 (pt) 2021-03-09
IL279205A (en) 2021-01-31
SG11202011964SA (en) 2020-12-30
CA3102372A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
SG11202012070YA (en) Methods and compositions for preventing or treating tissue calcification
EP3818085A4 (en) COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
EA202191358A1 (ru) Новые соединения и их применение в лечении
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
EP3968916A4 (en) GLAND TREATMENT DEVICES AND METHODS OF TREATING DRY EYE DISEASE
MX2021003262A (es) Metodos de tratamiento.
BR112022003935A2 (pt) Rebamipida para uso em profilaxia e tratamento de doença celíaca
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2021003265A (es) Metodos de tratamiento.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2020013306A (es) Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.
BR112022003918A2 (pt) Rebamipida para uso na prevenção e tratamento da doença de crohn